Notably, [18F]PARPi hasprogressed to clinical imaging of human head and neck cancer, whereit enabled detection of primary and metastatic lesions with favorabletumor-to-background contrast and without safety concerns. Together, these olaparib-derived tracers highlightthe clinical viability of PARP1-targeted PET imaging, with potentialextensions into neurodegenerative contexts, particularly in casesof compromised BBB or upregulated PARP1 expression. This evidence concerns the gene PARP1 and head and neck cancer.